Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

NCT04261686 | Completed FDA Device

• 1 other identifier: BDPI-19-001
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 11

Brief Summary

The objective of this study is to collect post-market, real-world safety and effectiveness data of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit.

Conditions

Arteriovenous Fistula

Outcome Measures

Primary Outcomes (11)

• Safety through 30 days

  Freedom from any adverse event(s), localized or systemic, that reasonably suggest the involvement of the AV access circuit that require or result in any of the following alone or in combination: additional interventions, in-patient hospitalization or prolongation of an existing hospitalization; or death.

  Through 30 days following index procedure

• Target Lesion Primary Patency (TLPP)

  The interval following the index intervention until the next clinically driven reintervention at or adjacent to the original treatment site, or until the extremity is abandoned for permanent access.

  1, 3, 6, 12, 18, 24, and 36 months following post-index procedure

• Access Circuit Primary Patency (ACPP)

  The interval following the index intervention until the next access thrombosis or repeated intervention.

  1, 3, 6, 12, 18, 24, and 36 months post index procedure

• Rate of Device and Procedure Related Adverse Events involving the access circuit

  Rate of device and procedure related adverse events (AEs) involving the access circuit.

  1, 3, 6, 12, 18, 24, and 36 months post index procedure.

• Total Number of Arteriovenous (AV) Access Circuit Reinterventions

  Number of reinterventions to the arteriovenous (AV) access circuit until access abandonment or through study completion.

  1, 3, 6, 12, 18, 24, and 36 months post index procedure

• Total Number of Target Lesion Reinterventions

  Number of reinterventions to maintain target lesion patency

  1, 3, 6, 12, 18, 24, and 36 months post index procedure

• Index of Patency Function (IPF)

  Time from the index study procedure to study completion or access abandonment divided by the number of visits for a reintervention performed on the arteriovenous (AV) access circuit in order to maintain vascular access for hemodialysis.

  1, 3, 6, 12, 18, 24, and 36 months post index procedure

• Index of Patency Function for Target Lesion

  Time from the index study procedure to study completion or complete access abandonment divided by the number of visits for a reintervention performed at the target lesion in order to maintain vascular access for hemodialysis.

  1, 3, 6, 12, 18, 24, and 36 months post index procedure

• Post-Intervention Secondary Patency

  The interval after the index intervention until the access is abandoned.

  1, 3, 6, 12, 18, 24, and 36 months post index procedure

• Acute Technical Success for Stent Graft Placement

  Defined as the successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure.

  At time of index procedure

• Acute Procedural Success

  Defined as anatomic success and resolution of the pre-procedural clinical indicator(s) (clinical success) of a hemodynamically significant stenosis

  At time of index procedure

Study Arms (1)

COVERA Vascular Covered Stent

OTHER

COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.

Device: Covera Vascular Covered Stent

Interventions

Covera Vascular Covered Stent DEVICE

This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent

COVERA Vascular Covered Stent

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.
• Subject must be either a male or non-pregnant female ≥ 21 years of age with an expected lifespan sufficient to allow for completion of all study procedures.
• Subject must be willing to comply with the protocol requirements, including clinical and telephone follow-up.
• Subject must have an upper extremity AV fistula that has undergone at least one successful dialysis session with two-needle cannulation, prior to the index procedure.
• Subject must have angiographic evidence of a stenosis ≥ 50% (by visual estimation) located in the venous outflow of the AV access circuit and present with clinical or hemodynamic evidence of AV fistula dysfunction.
• The target lesion must be ≤ 9cm in length. Note: multiple stenoses may exist within the target lesion.
• The reference vessel diameter of the adjacent non-stenotic vein must be between 5.0 and 9.0mm.

You may not qualify if:

• The subject is dialyzing with an AV graft.
• The target lesion has had a corresponding thrombosis treated within 7 days prior to the index procedure.
• The hemodialysis access is located in the lower extremity.
• The subject has an infected AV fistula or uncontrolled systemic infection.
• The subject has a known uncontrolled blood coagulation/bleeding disorder.
• The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.
• The subject has a known hypersensitivity to nickel-titanium (Nitinol) or tantalum.
• The subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
• The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.
• Additional stenotic lesions (≥ 50%) in the venous outflow that are \> 3cm from the edge of the target lesion and are not successfully treated (defined as ≤ 30% residual stenosis) prior to treating the target lesion.
• An aneurysm or pseudoaneurysm is present within the target lesion.
• The location of the target lesion would require the COVERATM Vascular Covered Stent be deployed across the elbow joint.
• The target lesion is located within a stent.
• The location of the target lesion would require that the COVERA™ Vascular Covered Stent be deployed at or across the segment of fistula utilized for dialysis needle puncture (i.e., "cannulation zone").
• The location of the target lesion would require that the COVERA™ Vascular Covered Stent be placed in the central veins (subclavian, brachiocephalic, Superior Vena Cava (SVC)) or under the clavicle at the thoracic outlet.

Sponsors & Collaborators

• C. R. Bard: lead

Study Sites (11)

Arizona Kidney Disease and Hypertension Center Medical Research Services

Phoenix, Arizona, 85012, United States

Location

Yale University

New Haven, Connecticut, 06511, United States

Location

Chicago Access Care

Westmont, Illinois, 60559, United States

Location

Kidney Care & Transplant Services of New England

West Springfield, Massachusetts, 01089, United States

Location

Michigan Vascular Center

Flint, Michigan, 48507, United States

Location

University of Minnesota Medical Center

Minneapolis, Minnesota, 55455, United States

Location

Minnesota Vascular and Surgery Center

New Brighton, Minnesota, 55112, United States

Location

North Carolina Nephrology

Raleigh, North Carolina, 27610, United States

Location

Providence Access Care

Providence, Rhode Island, 02906, United States

Location

Dallas Renal Group

Dallas, Texas, 75208, United States

Location

San Antonio Kidney and Disease Access Center

San Antonio, Texas, 78216, United States

Location

Related Publications (1)

• Dolmatch B, Saber T, Underwood M; and AVeNEW PAS trial investigators. Six-Month Outcomes from the Prospective, Multi-Center, Non-Randomized Clinical Study of the COVERA() Arterio VeNous (AV) Stent Graft in the Treatment of Stenosis in the VEnous OutfloW of AV Fistula Access Circuits (AVeNEW PAS). Cardiovasc Intervent Radiol. 2025 Apr;48(4):460-471. doi: 10.1007/s00270-024-03930-7. Epub 2025 Jan 9.

  PMID: 39789255 DERIVED

MeSH Terms

Conditions

Arteriovenous Fistula

Condition Hierarchy (Ancestors)

Arteriovenous Malformations; Vascular Malformations; Cardiovascular Abnormalities; Cardiovascular Diseases; Vascular Fistula; Vascular Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Fistula; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Bart Dolmatch, M.D.

  The Palo Alto Medical Foundation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2020
• First Posted: February 10, 2020
• Study Start: July 3, 2020
• Primary Completion: September 16, 2025
• Study Completion: September 16, 2025
• Last Updated: December 16, 2025

Record last verified: 2025-12

Locations

US (11)